Article · 28 Mar 2025
Conference abstract
HIV vaccine development: Is a moral wrong occurring?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Given the extent of the HIV epidemic, the potential benefit of, and moral reason for, HIV vaccine development is enormous, especially if we have greater reason to benefit the worst off. These are reasons to provide this benefit as soon as possible. Impediments to successful vaccine development come at the cost of preventing or delaying these benefits, allowing the harm of HIV infection to persist, and perhaps increase. Impediments range from lack of political, social, ethical, and financial support to inefficient organisation of global HIV research efforts, pursuit of ineffective research programs, and failure to pursue more effective options. Competing values may explain or justify some impediments, however, the immense moral value of an effective vaccine remains. Some impediments impose the moral opportunity cost of foregone counterfactual benefits. As an example of this, Marc Van Regenmortel has argued that structure-based reverse vaccinology is an ineffective research program for HIV vaccine development, and that other methods should be used instead. Where researchers and funders are devoting scarce resources to ineffective research programmes when those resources could be used more effectively to pursue the good via other means, moral opportunity cost accrues, which may constitute a moral failure, or wrong. This also reveals HIV vaccine development as freighted with empirical, scientific, philosophical and applied ethical considerations. The more those working in HIV vaccinology are able and willing to consider and discuss their work in all these terms, the more likely the great good that vaccinology is capable of achieving can be realised.
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 2014
Taming the Monster: Need for Africa-initiated, Africa-led HIV Vaccine Research and Development Advocacy in Africa
Review article · 2014
HIV-1 Diversity in Tanzania and its Implication toward Development of Effective Vaccines: A Review Article
Research article · 2013
Development of Anti HIV Gp120 and HIV Gp41 Peptide Vaccines
Conference abstract
Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine
More from this journal
The newest in Journal of Vaccines & Vaccination.
Article · 29 Aug 2026
Advancing Immune-Based Disease Management through Therapeutic Vaccines
Article · 29 Aug 2026
Advances in Adjuvant Development for Enhanced Vaccine Performance and Long-Term Immune Protection
Article · 20 Jun 2026
Herd Immunity and Its Role in Controlling Infectious Diseases
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vaccines & Vaccination
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Mike King”
